Argonaut has acted as Joint Lead Manager to Botanix Pharmaceuticals Ltd (ASX: BOT) (“Botanix”) in its oversubscribed placement of A$15 million to new and existing institutional and sophisticated investors.
The funds raised under the placement provides financial capacity for Botanix to accelerate key clinical development programmes and broader commercialisation strategy of Botanix’s dermatology products, BTX1503 and BTX1204, and to explore further the commercial potential of the Permetrex TM technology.
Botanix’s Executive Director, Matthew Callahan said:
“The exceptional support is a clear endorsement by the investment community of Botanix’s business strategy, substantial clinical progress, development of innovative product opportunities and exciting growth prospects.”
Argonaut is delighted to provide ongoing support to Botanix and looks forward to working with the Company as it continues to create further value for shareholders.
Additional information regarding Botanix can be found on the Company’s website at www.botanixpharma.com.